User profiles for Kirsten Littlefield
 | Kirsten E LittlefieldPhD student, University of Texas Medical Branch Verified email at utmb.edu Cited by 1668 |
[HTML][HTML] Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population
…, JR Shapiro, SE Benner, K Littlefield… - The Journal of …, 2020 - Am Soc Clin Investig
Convalescent plasma is a leading treatment for coronavirus disease 2019 (COVID-19), but
there is a paucity of data identifying its therapeutic efficacy. Among 126 potential …
there is a paucity of data identifying its therapeutic efficacy. Among 126 potential …
[HTML][HTML] SARS-CoV-2–specific CD8+ T cell responses in convalescent COVID-19 individuals
…, SE Benner, EU Patel, K Littlefield… - The Journal of …, 2021 - Am Soc Clin Investig
Characterization of the T cell response in individuals who recover from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is critical to understanding its …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is critical to understanding its …
Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers
…, M Keruly, CS Kirby, E Klock, K Littlefield… - Journal of Clinical …, 2021 - Am Soc Microbiol
Accurate serological assays to detect antibodies to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 …
coronavirus 2 (SARS-CoV-2) are needed to characterize the epidemiology of SARS-CoV-2 …
SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors
Background Convalescent plasma therapy is a leading treatment for conferring temporary
immunity to COVID-19–susceptible individuals or for use as post-exposure prophylaxis. …
immunity to COVID-19–susceptible individuals or for use as post-exposure prophylaxis. …
[HTML][HTML] Durable SARS-CoV-2 B cell immunity after mild or severe disease
Multiple studies have shown loss of severe acute respiratory syndrome coronavirus 2–specific
(SARS-CoV-2–specific) antibodies over time after infection, raising concern that humoral …
(SARS-CoV-2–specific) antibodies over time after infection, raising concern that humoral …
A bacterial extracellular vesicle‐based intranasal vaccine against SARS‐CoV‐2 protects against disease and elicits neutralizing antibodies to wild‐type and Delta …
…, I Sitaras, R Zhou, C Caputo, K Littlefield… - Journal of …, 2022 - Wiley Online Library
Several vaccines have been introduced to combat the coronavirus infectious disease‐2019 (COVID‐19)
pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐…
pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS‐…
Sex differences in lung imaging and SARS-CoV-2 antibody responses in a COVID-19 golden Syrian hamster model
In the coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), more severe outcomes are reported in males …
syndrome coronavirus 2 (SARS-CoV-2), more severe outcomes are reported in males …
Markers of polyfunctional SARS-CoV-2 antibodies in convalescent plasma
Convalescent plasma is a promising therapy for coronavirus disease 2019 (COVID-19), but
the antibody characteristics that contribute to efficacy remain poorly understood. This study …
the antibody characteristics that contribute to efficacy remain poorly understood. This study …
Cytokine and chemokine levels in coronavirus disease 2019 convalescent plasma
…, AG Abraham, K Littlefield… - Open Forum …, 2021 - academic.oup.com
Background The efficacy of coronavirus disease 2019 (COVID-19) convalescent plasma (CCP)
is primarily ascribed as a source of neutralizing anti-severe acute respiratory syndrome …
is primarily ascribed as a source of neutralizing anti-severe acute respiratory syndrome …
Pregnancy alters interleukin-1 beta expression and antiviral antibody responses during severe acute respiratory syndrome coronavirus 2 infection
…, R Reddy, K Voegtline, S Olson, K Littlefield… - American journal of …, 2021 - Elsevier
Background Severe acute respiratory syndrome coronavirus 2, the disease-causing
pathogen of the coronavirus disease 2019 pandemic, has resulted in morbidity and mortality …
pathogen of the coronavirus disease 2019 pandemic, has resulted in morbidity and mortality …